Antioxidant treatment of tardive dyskinesia (Q41185188)

28 September 2017

1 reference

title

Antioxidant treatment of tardive dyskinesia (English)

1 reference

28 September 2017

1 reference

Rotrosen J

1

1 reference

28 September 2017

Adler L

2

1 reference

28 September 2017

Lohr J

3

1 reference

28 September 2017

Edson R

4

1 reference

28 September 2017

Lavori P

5

1 reference

28 September 2017

publication date

1 August 1996

1 reference

Prostaglandins, Leukotrienes and Essential Fatty Acids

28 September 2017

published in

1 reference

28 September 2017

volume

55

1 reference

28 September 2017

issue

1-2

1 reference

28 September 2017

page(s)

77-81

1 reference

A systematic investigation of tardive dyskinesia in inpatients

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Gender differences in tardive dyskinesia: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Prospective study of tardive dyskinesia incidence in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Tardive Dyskinesia and Hospital Discharge

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Prediction of relapse in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Mortality of patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Mortality rate in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Therapeutic strategies against tardive dyskinesia. Two decades of experience

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Alpha-tocopherol in tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Oxygen radicals and neuropsychiatric illness. Some speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

The increase of phospholipid bilayer rigidity after lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Differential effect of lipid peroxidation on membrane fluidity as determined by electron spin resonance probes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

The role of lipid peroxidation in the induction of cation transport in rat liver mitochondria. The antioxidant effect of oligomycin and dicyclohexylcarbodiimide

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Oxygen radicals and plasma membrane potential

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Lipid peroxidation in mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Phospholipase activity and plasma membrane homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Effect of chlorphromazine on central nervous system concentrations of manganese, iron, and copper

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Transition metals as catalysts of "autoxidation" reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Neuropathological findings in three cases of persistent dyskinesia following phenothiazine medication

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Iron pigment in the brain of a man with tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Essential fatty acids in plasma phospholipids in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Vitamin E in the treatment of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Treatment of tardive dyskinesia with vitamin E.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

alpha-Tocopherol treatment for tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: a replication study

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

Effectiveness of vitamin E for treatment of long-term tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0952-3278%2896%2990149-0

7 January 2021

10.1016/S0952-3278(96)90149-0

Identifiers

DOI

1 reference

28 September 2017

1 reference